Media

WILSON THERAPEUTICS AB (PUBL) INTERIM REPORT JANUARY 1 – JUNE 30, 2016

Nordic Nanovector completes recruitment of the first cohorts of Arm 3 and Arm 4 of expanded Phase 1/2 study of Betalutin® in NHL patients

NEXSTIM PLC HALF-YEARLY REPORT 1 JANUARY – 30 JUNE 2016 (UNAUDITED)

WILSON THERAPEUTICS APPOINTS VINCENT METZLER AS VICE PRESIDENT COMMERCIAL PLANNING & LAUNCH STRATEGY

BONESUPPORT™ Receives FDA Approval to Initiate IDE Clinical Study

ALTIMMUNE RECEIVES BARDA CONTRACT OF UP TO $120.2 MILLION TO FUND CLINICAL DEVELOPMENT OF FIRST-IN-CLASS ANTHRAX VACCINE CANDIDATE NASOSHIELD

Onxeo Reports First-Half 2016 Business Update and Consolidated Financials

Cash position and revenue for the 1st semester of 2016